Gyre Therapeutics, Inc. - Common Stock GYRE 深 沪
已收盘 11-07 16:00:00 美东时间
7.21
-0.130
-1.77%
华盛通- 最 高7.30
- 今 开7.27
- 成交量 4.75万股
- 最 低 7.12
- 昨 收 7.34
- 总市值 6.94亿
- 52周最高 14.4228
- 市盈率 静 149.90
- 换手率 0.05%
- 52周最低 6.11
- 委 比 79.34%
- 总股本 9631.32万
- 历史最高 29271.2116
- 量 比 1.01
- 振 幅 2.45%
- 历史最低 -19.80
- 每 手 1
- 风险率 2.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 7, 2025
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
11-07 19:11
Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.02) by 250 percent. This is a 200 percent increase over earnings of $0.01 per share from the
11-07 19:07
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
Gyre Therapeutics subsidiary completes enrollment of 272 patients in China for Phase 3 trial of Pirfenidone capsules for pneumoconiosis, a chronic occupational lung disease. The trial, conducted at 18 research centers, aims to assess efficacy and safety over 52 weeks. Pneumoconiosis, caused by long-term dust exposure, has no approved targeted treatment in China, highlighting unmet medical need. Pirfenidone, an antifibrotic drug approved for idiop...
10-15 11:00
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
Jefferies Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $16
Jefferies analyst Roger Song initiates coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rating and announces Price Target of $16.
10-10 19:28
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Gyre Therapeutics announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 12:30 p.m. ET. The live webcast and replay will be available on Gyre’s website. Gyre focuses on developing therapies for fibrosis, particularly Hydronidone for liver fibrosis, and is expanding its pipeline in China through Gyre Pharmaceuticals.
09-05 20:05
Gyre Therapeutics Appoints Dan Weng to Board
Gyre Therapeutics ( ($GYRE) ) has shared an update. On August 18, 2025, Gyre Th...
08-22 19:28
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Gyre Therapeutics appoints Dan Weng, M.D., to its Board of Directors. Dr. Weng brings nearly four decades of experience in global clinical trials and holds leadership roles in several prominent CROs. Gyre, a biopharmaceutical company, focuses on developing therapies for organ fibrosis. Its flagship product, ETUARY® (Pirfenidone capsule), is a leading treatment for IPF in China. The company is also advancing Hydronidone and other therapies for var...
08-22 11:00
Gyre Therapeutics Appoints Ping Zhang as Interim CEO
Gyre Therapeutics ( ($GYRE) ) just unveiled an update. On August 5, 2025, Gyre ...
08-12 04:45
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
Gyre Therapeutics has initiated a Phase 1 clinical trial for its novel ETA receptor antagonist, F230, targeting pulmonary arterial hypertension (PAH). This marks Gyre's entry into the PAH field, a rare and severe cardiovascular condition with limited treatment options. F230, licensed from Eisai Co., Ltd., is designed to selectively block the ETA receptor to reduce pulmonary vascular remodeling and lower pulmonary pressure. The trial aims to asses...
06-10 11:00
